title: Pharmacological interaction between gabapentin and glibenclamide in the formalin test in the diabetic rat.
abstract: There is evidence that local peripheral administration of gabapentin produces antinociception through the activation of the ATP-sensitive K+-channel. However, this interaction has not been evaluated systemically, nor in diabetic rat. This work was undertaken to determine whether glibenclamide has any effect on the systemic antinociception induced by gabapentin. Inflammatory pain was induced by injection of formalin in diabetic rats. Reduction of flinching behavior was considered as antinociception. Systemic administration of gabapentin (10-56 mg/kg, i.p.) produced a dose-dependent antinociception in both phases of the formalin test. Also, glibenclamide (1-10 mg/kg, s.c.) blocked the gabapentin-induced antinociception. Given alone glibenclamide did not significantly modify formalin-induced nociception in diabetic rats. Our data suggest that gabapentin is able to reduce formalin-induced nociception in streptozotocin-injected rats. In addition, these data are consistent with gabapentin-mediated activation of ATP-sensitive-K+ channels to produce systemic antinociception in the formalin test in diabetic rats.
authors: Area Académica de Medicina del Instituto de Ciencias de la Salud, Universidad Autónoma del Estado de Hidalgo, Pachuca, Hidalgo, Mexico. mario_i_ortiz@hotmail.com
authors: Mario I
authors: MI
authors: Ortiz
authors: Héctor A
authors: HA
authors: Ponce-Monter
authors: Eduardo
authors: E
authors: Fernández-Martínez
authors: Arturo
authors: A
authors: Macías
authors: Eduardo
authors: E
authors: Rangel-Flores
authors: Jeannett A
authors: JA
authors: Izquierdo-Vega
authors: Manuel
authors: M
authors: Sánchez-Gutiérrez
mesh_terms: D000588:Amines / Q000627:therapeutic use*; D000818:Animals; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000503:physiopathology; D004347:Drug Interactions; D000077206:Gabapentin; D005905:Glyburide / Q000627:therapeutic use*; D054086:KATP Channels / Q000187:drug effects; D008297:Male; D010147:Pain Measurement; D051381:Rats; D017208:Rats, Wistar; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use*
chemical_list: D000588:Amines; D003509:Cyclohexanecarboxylic Acids; D054086:KATP Channels; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D005905:Glyburide